A phase 2, 24-week, adaptive, open label, sequential cohort trial to evaluate the efficacy, safety, tolerability and pharmacokin

A phase 2, 24-week, adaptive, open label, sequential cohort trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of pf-06730512 following multiple doses in adult subjects with focal segmental glomerulosclerosis (fsgs).

Obert

Codi protocol: C0221002
Codi EudraCT: 2019-003607-35
Grup de recerca: Nefrologia i Trasplantament Renal
Servei: Nefrologia
Investigador/a principal: Soler Romeo, Maria Jose
Malaltia: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase II
Estat: Reclutant voluntaris